Starane Shepherd, MD
Neurocritical Care · Atlanta, GANPI 1922391523
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Immedica Pharma US, Inc. at 33.2% of the total. Reporting peaked in 2023 at $89 and has fallen 55.0% since, to $40 in 2025.
Across 8 payments — averaging $33.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immedica Pharma US, Inc.$89
- Medtronic$40
- Johnson & Johnson$40
- Edwards Lifesciences$35
- ZOLL Circulation Inc$31
- Stryker$17
- plus $16 from 1 others
Across 4 payments — averaging $6537.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$26K
What the payments were for
- Food & beverage$268100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immedica Pharma US, Inc. | 1 | $89 |
| Medtronic | 2 | $40 |
| Johnson & Johnson | 1 | $40 |
| Edwards Lifesciences | 1 | $35 |
| ZOLL Circulation Inc | 1 | $31 |
| Stryker | 1 | $17 |
| Haemonetics Corporation | 1 | $16 |
How this compares
Too few neurocritical care providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurocritical care in Atlanta
- Anand SarmaAtlanta$2K
- Anantha VellipuramAtlanta$361
- Muthu BhaskaranAtlanta$235
- Syed Talha QasmiAtlanta$123
- Michael Vincent MendozaAtlanta$89
- Samuel TsappidiAugusta$54K
- Manjunath MarkandayaGainesville$12K
- Manan ShahAugusta$3K
- Klepper GarciaAugusta$997
- Christopher HornMarietta$897
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.